Novel NQO1 substrate, inhibiting cancer cell (NQO1-rich A549 cell line) growth

Novel Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 (MLL1) Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia

Novel potent blocker of mixed lineage leukemia 1 (MLL1)-WDR5 interaction, inhibiting MLL1 complex H3K4 methyltransferase activity

Novel potent and broad-spectrum antiviral agent, acting as a chain terminator for viral RNA polymerase

Potent inhibitor of Trypanosoma brucei N-myristoyltransferase (TbNMT) with markedly improved blood-brain barrier permeability

Potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory pain

Novel transmission blocker of antimalarials, targeting male gametes

Novel activator of the GUS reporter activity, specific increasing in stumpy reporter gene expression

First-generation allosteric EGFR inhibitor, binding to the allosteric site of EGFR along with ATP that leads to inhibition of cell proliferation and arrest of EGFR L858R/T790M/C797S signalling

Novel selective BTK degrader, demonstrating prolonged pharmacodynamic effects

Novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction

Novel potent and selective TEAD autopalmitoylation inhibitor, inhibiting TEADs transcription activity and downstream gene expression

Novel, Potent and Selective Histone Methyltransferase SET7 Inhibitor

Novel, Potent and Selective Histone Methyltransferase SET7 Inhibitor

Novel, Selective Histone Methyltransferase SET7 Inhibitor

Novel PRC2 Inhibitor, Targeting EZH2-EED Interaction

Novel potent and selective DCN1-UBC12 inhibitor for anticardiac fibrotic effects, specifically targetinbg DCN1 at molecular and cellular levels, effectively reversing angiotensin (Ang) II-induced cardiac fibroblast activation

Novel potent CDK2 inhibitor with selectivities above 10-fold over CDK1/4/6/7/9/12 above 10-fold, displaying anti-proliferative activity against A2058 melanoma and MV4-11 leukemia cell lines and low toxicity on human normal cell lines, inhibiting CDK2-medi

Highly potent agonist for group II mGlu receptors

Novel inhibitor of lysine methyltransferase G9a

Activator of IK and SK channels

Novel potent EZH2 inhibitor

Novel potent EZH2 inhibitor

Novel potent CBP bromodomain inhibitor with a TR-FRET IC50 value of 19.5 ± 1.1 nM and over 400-fold of selectivity against BRD4 bromodomains

Novel potent BPTF-BRD inhibitor, showing selectivities 100-fold higher than those of other BRD targets

Novel potent BPTF-BRD inhibitor, showing selectivities 100-fold higher than those of other BRD targets, significantly inhibiting leukemia cell proliferation

Inhibitor of N-methyl transferases (NMT), preventing the formation of Parkinson's syndrome neurotoxins via methylation of non-methylated pre-neurotoxins.

Novel inhibitor of menin-MLL interaction

Novel inhibitor of menin-MLL interaction

Novel inhibitor of menin-MLL interaction